JP2010505822A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010505822A5 JP2010505822A5 JP2009531332A JP2009531332A JP2010505822A5 JP 2010505822 A5 JP2010505822 A5 JP 2010505822A5 JP 2009531332 A JP2009531332 A JP 2009531332A JP 2009531332 A JP2009531332 A JP 2009531332A JP 2010505822 A5 JP2010505822 A5 JP 2010505822A5
- Authority
- JP
- Japan
- Prior art keywords
- gos
- composition
- polymerization
- composition according
- degree
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 25
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims 20
- 150000003271 galactooligosaccharides Chemical class 0.000 claims 20
- 238000006116 polymerization reaction Methods 0.000 claims 9
- 241000894007 species Species 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 102000009016 Cholera Toxin Human genes 0.000 claims 6
- 108010049048 Cholera Toxin Proteins 0.000 claims 6
- 235000016709 nutrition Nutrition 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000030090 Acute Disease Diseases 0.000 claims 3
- 208000017667 Chronic Disease Diseases 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 230000037406 food intake Effects 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 241000588724 Escherichia coli Species 0.000 claims 2
- 238000010828 elution Methods 0.000 claims 2
- 230000000688 enterotoxigenic effect Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims 1
- 206010008631 Cholera Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 101710146739 Enterotoxin Proteins 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 239000005862 Whey Substances 0.000 claims 1
- 102000007544 Whey Proteins Human genes 0.000 claims 1
- 108010046377 Whey Proteins Proteins 0.000 claims 1
- 102000005936 beta-Galactosidase Human genes 0.000 claims 1
- 108010005774 beta-Galactosidase Proteins 0.000 claims 1
- 239000003729 cation exchange resin Substances 0.000 claims 1
- 150000002016 disaccharides Chemical class 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000000147 enterotoxin Substances 0.000 claims 1
- 231100000655 enterotoxin Toxicity 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 150000002772 monosaccharides Chemical class 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- 239000012466 permeate Substances 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06076810 | 2006-10-02 | ||
| PCT/NL2007/050475 WO2008041843A1 (en) | 2006-10-02 | 2007-10-01 | Inhibition of cholera toxins by galatooligosaccharides (gos) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010505822A JP2010505822A (ja) | 2010-02-25 |
| JP2010505822A5 true JP2010505822A5 (enExample) | 2010-12-16 |
Family
ID=37533486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009531332A Pending JP2010505822A (ja) | 2006-10-02 | 2007-10-01 | ガラクトオリゴ糖（ｇｏｓ）によるコレラ毒素の抑制 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8202842B2 (enExample) |
| EP (1) | EP2076271B1 (enExample) |
| JP (1) | JP2010505822A (enExample) |
| AT (1) | ATE524190T1 (enExample) |
| DK (1) | DK2076271T3 (enExample) |
| ES (1) | ES2373592T3 (enExample) |
| PL (1) | PL2076271T3 (enExample) |
| PT (1) | PT2076271E (enExample) |
| SI (1) | SI2076271T1 (enExample) |
| WO (1) | WO2008041843A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006012536A2 (en) | 2004-07-22 | 2006-02-02 | Ritter Andrew J | Methods and compositions for treating lactose intolerance |
| FR2907687B1 (fr) * | 2006-10-30 | 2008-12-26 | Applexion | Procede de purification de sialyllactose par chromatographie |
| US20110223248A1 (en) * | 2007-12-12 | 2011-09-15 | Ritter Pharmaceuticals, Inc. | Methods and compositions for treating lactose intolerance |
| KR20170053733A (ko) | 2009-02-24 | 2017-05-16 | 리터 파마슈티컬즈 인코오포레이티드 | 프리바이오틱 제제 및 사용 방법 |
| US8785160B2 (en) | 2009-02-24 | 2014-07-22 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
| JP2012520325A (ja) † | 2009-03-13 | 2012-09-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | プレバイオティックオリゴ糖 |
| US20110189342A1 (en) * | 2010-02-01 | 2011-08-04 | Jeong Hea-Seok | High-purity galactooligosaccharides and uses thereof |
| NL2007931C2 (en) | 2011-12-07 | 2013-06-10 | Friesland Brands Bv | Methods for providing sialylated oligosaccharides and products obtainable thereby. |
| WO2015095747A1 (en) | 2013-12-20 | 2015-06-25 | Abbott Laboratories | Oral rehydration composition with oligosaccharides |
| EP3530743A1 (en) | 2018-02-21 | 2019-08-28 | Cambridge Glycoscience Ltd | Method of production |
| AU2019321182B2 (en) | 2018-08-15 | 2025-01-09 | Cambridge Glycoscience Ltd. | Novel compositions, their use, and methods for their formation |
| CA3108735A1 (en) | 2018-09-06 | 2020-03-12 | Frieslandcampina Nederland B.V. | Bifidogenic hypoallergenic gos compositions and methods for providing the same involving beta-galactosidase from a strain of lactobacillus delbrueckii ssp bulgaricus |
| KR102874614B1 (ko) * | 2018-11-08 | 2025-10-22 | 디에스엠 아이피 어셋츠 비.브이. | 위장 대사물질을 조절하는 방법 |
| US11911405B2 (en) * | 2018-11-08 | 2024-02-27 | Dsm Ip Assets B.V. | Methods of selectively modulating gastrointestinal microbial growth |
| EP4013240A1 (en) | 2019-08-16 | 2022-06-22 | Cambridge Glycoscience Ltd | Methods of treating biomass to produce oligosaccharides and related compositions |
| CN115279208B (zh) | 2019-12-12 | 2024-12-17 | 剑桥糖质科学有限公司 | 低糖多相食品 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0614870B2 (ja) * | 1986-12-15 | 1994-03-02 | 株式会社ヤクルト本社 | ガラクトオリゴ糖の製造法 |
| NZ222902A (en) | 1986-12-15 | 1990-08-28 | Yakult Honsha Kk | Method for producing galactooligosaccharide |
| ZA991410B (en) | 1998-02-23 | 1999-10-06 | Synsorb Biotech Inc | Compounds and methods for the treatment of bacterial dysentry using antibiotics and toxin binding oligosaccharide compositions. |
| US6630452B2 (en) * | 2000-02-17 | 2003-10-07 | Wyeth | Nutritional formulation containing prebiotic substances |
| FR2838452B1 (fr) | 2002-04-10 | 2004-07-09 | Eurodia Ind | Procede de production en continu de galacto oligosaccharides |
| GB0229015D0 (en) | 2002-12-12 | 2003-01-15 | Novartis Nutrition Ag | New Compound |
| GB0308104D0 (en) * | 2003-04-08 | 2003-05-14 | Novartis Nutrition Ag | Organic compounds |
| MXPA05010349A (es) | 2003-06-30 | 2006-03-08 | Clasado Inc | Composicion novedosa de galactooligosacaridos y preparacion de la misma. |
| JP4847321B2 (ja) | 2003-07-04 | 2011-12-28 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼーション | 金属化合物を製造するための方法および装置 |
| US20070196890A1 (en) | 2003-10-02 | 2007-08-23 | Jelena Vulevic | Prebiotic effect analysis |
-
2007
- 2007-10-01 SI SI200730768T patent/SI2076271T1/sl unknown
- 2007-10-01 JP JP2009531332A patent/JP2010505822A/ja active Pending
- 2007-10-01 US US12/443,565 patent/US8202842B2/en not_active Expired - Fee Related
- 2007-10-01 EP EP07834613A patent/EP2076271B1/en not_active Not-in-force
- 2007-10-01 ES ES07834613T patent/ES2373592T3/es active Active
- 2007-10-01 PT PT07834613T patent/PT2076271E/pt unknown
- 2007-10-01 WO PCT/NL2007/050475 patent/WO2008041843A1/en not_active Ceased
- 2007-10-01 PL PL07834613T patent/PL2076271T3/pl unknown
- 2007-10-01 DK DK07834613.7T patent/DK2076271T3/da active
- 2007-10-01 AT AT07834613T patent/ATE524190T1/de not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010505822A5 (enExample) | ||
| Kunz et al. | Health promoting aspects of milk oligosaccharides | |
| Yan et al. | Lactobacillus acidophilus alleviates type 2 diabetes by regulating hepatic glucose, lipid metabolism and gut microbiota in mice | |
| Ramezani et al. | The gut microbiome, kidney disease, and targeted interventions | |
| Nakamura et al. | Concentrations of sialyloligosaccharides in bovine colostrum and milk during the prepartum and early lactation | |
| Dai et al. | Effects of α-galactooligosaccharides from chickpeas on high-fat-diet-induced metabolic syndrome in mice | |
| EP2076271B1 (en) | Inhibition of cholera toxins by galatooligosaccharides (gos) | |
| Kunz et al. | Potential anti-inflammatory and anti-infectious effects of human milk oligosaccharides | |
| JP2012532195A5 (enExample) | ||
| CA2442053A1 (en) | Composition comprising a prebiotic for decreasing inflammatory process and abnormal activation of non-specific immune parameters | |
| EP2011799B1 (en) | Process for obtaining pure monosialoganglioside GM1 for medical use | |
| CN112638181B (zh) | 双歧杆菌低变应原GOS组合物及涉及来自德氏乳酸杆菌保加利亚亚种菌株的β-半乳糖苷酶的其提供方法 | |
| US20120135957A1 (en) | Compositions containing mixtures of fermentable fibers | |
| JP2015523362A5 (enExample) | ||
| Vanholder et al. | An update on protein-bound uremic retention solutes | |
| WO2005072045A3 (en) | The combined use of glp-1 agonists and gastrin for regulating blood glucose levels | |
| Rehman et al. | Morchella esculenta polysaccharide attenuate obesity, inflammation and modulate gut microbiota | |
| Vilahur et al. | Lactobacillus plantarum CECT 7315/7316 intake modulates the acute and chronic innate inflammatory response | |
| Wiernsperger | Treatment strategies for fatty liver diseases | |
| KR20240026882A (ko) | 락토바실러스 뮤코세 및 수용성 식이섬유의 조합물을 사용한 방법 및 조성물 | |
| van der Toorn et al. | Biological relevance of goat milk oligosaccharides to infant health | |
| Ye et al. | Phage cocktail alleviated type 2 diabetes by reshaping gut microbiota and decreasing proinflammatory cytokines | |
| Gu et al. | Hyperuricemia-induced complications: dysfunctional macrophages serve as a potential bridge | |
| EA200802038A1 (ru) | Фармацевтическая композиция энтеросорбента и пребиотиков, лекарственные формы и способ профилактики и лечения заболеваний желудочно-кишечного тракта | |
| AU2013217176B2 (en) | Ladostigil therapy for immunomodulation |